ライフサイエンスコーパス: promoter methylation

1 t of this association was mediated by ICAM-1 promoter methylation.

2 xpression, independently from changes in its promoter methylation.

3 cing of SDH genes, and determination of SDHC promoter methylation.

4 d for quantitative assessment of RASSF1A DNA promoter methylation.

5 e found evidence for epigenetic silencing by promoter methylation.

6 ntified 2 clusters with different degrees of promoter methylation.

7 trimethylation (H3K9me3) to suggest greater promoter methylation.

8 PTSD effects on clinical variables and GR-1F promoter methylation.

9 tumors without causal germline mutations or promoter methylation.

10 HPV) types and for FAM19A4 and microRNA124-2 promoter methylation.

11 eness in prostatic fibroblasts induced Gstp1 promoter methylation.

12 ssociated with clinical indicators and GR-1F promoter methylation.

13 etic lethality in tumors that display HSPA1A promoter methylation.

14 of human colorectal cancers, mainly through promoter methylation.

15 on for Dnmt1 in both maintenance and de novo promoter methylation.

16 ce of loss of heterozygosity, mutations, and promoter methylation.

17 gland level genomic instability for MSI and promoter methylation.

18 This likely occurs via promoter methylation.

19 ators and mechanisms underlying RASSF1A gene promoter methylation.

20 d H3K27 acetylation and decreased PGC-1alpha promoter methylation.

21 Expression of CXCL5 was regulated by promoter methylation.

22 s significant heterogeneity for both MSI and promoter methylation.

23 ents was also associated with increased APNG promoter methylation.

24 smoke condensate selectively increased SMAD3 promoter methylation.

25 ssion in CRC lines was associated with Cdx-1 promoter methylation.

26 nocytes does not involve changes in proximal promoter methylation.

27 of TMZ sensitivity are not explained by MGMT promoter methylation.

28 pproximately 37% single deletion) but not to promoter methylation.

29 xpression occurs at 7 weeks independently of promoter methylation.

30 lls and that its expression is controlled by promoter methylation.

31 O(6-)methylguanine-DNA methyltransferase via promoter methylation.

32 , this distribution was highly predictive of promoter methylation.

33 e have shown that PDLIM2 repression involves promoter methylation.

34 gulation of resistin in monocytes along with promoter methylation.

35 C3A-Variant1 gene expression was silenced by promoter methylation.

36 ion; and (c) methylguanine methyltransferase promoter methylation.

37 ndependent of rhMAOA-LPR genotype and global promoter methylation.

38 on, methyl-guanine-methyl-transferase (MGMT) promoter methylation, age, Karnofsky performance score).

39 utcomes (P = 0.50), but the presence of TERT promoter methylation, alone or concurrent with promoter

40 ations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype

41 ation of TERT promoter mutations, as well as promoter methylation, an epigenetic alteration also link

42 decreased osteogenic marker gene expression; promoter methylation analysis by pyrosequencing showed n

43 SDHC promoter methylation analysis of 32 paraffin embedded tu

44 PCK1 promoter methylation analysis using bisulfite sequencing

45 findings suggest that abnormal insulin (INS) promoter methylation and altered transcription factor ex

46 Genes with promoter methylation and concordantly suppressed express

47 he tissue-relevant biology, showing distinct promoter methylation and evolution patterns (e.g., brain

48 wed significant negative correlation between promoter methylation and expression of an alternative tr

49 The correlation between promoter methylation and expression was investigated by

50 istic analyses correlated changes in miR-192 promoter methylation and expression with epithelial-mese

51 Deleterious low VDR levels resulted from promoter methylation and gene deletion in metastases.

52 The global correlation between promoter methylation and gene expression (as measured by

53 We go on to perform the first global DNA promoter methylation and gene expression analyses compar

54 The inverse correlation between promoter methylation and gene expression gradually stren

55 BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras

56 Gene-set testing of the 127 RDMs showed that promoter methylation and gene expression were reciprocal

57 here we observed inverse correlation between promoter methylation and gene expression.

58 We demonstrate that PTPRT promoter methylation and gene silencing is reversible in

59 to identify significant associations between promoter methylation and gland histological type and MSI

60 to identify significant associations between promoter methylation and gland histological type and MSI

61 wed that miR-23b expression is controlled by promoter methylation and has great promise as a diagnost

62 Manipulation of promoter methylation and histone acetylation represents

63 However, the association between RASSF1A promoter methylation and HNSCC remains unclear and contr

64 Correlation of MGMT promoter methylation and improved OS and PFS was retaine

65 ylation inhibitor, which also decreases Cdh1 promoter methylation and increases Cdh1 mRNA and protein

66 ate the poorly understood mechanisms of MLH1 promoter methylation and loss of expression.

67 Conversely, high levels of promoter methylation and low levels of EREG expression w

68 regulate CD133 transcription in GSC and that promoter methylation and methyl-DNA-binding proteins cau

69 samples were collected for analysis of GR-1F promoter methylation and of cortisol levels in response

70 of O(6)-methylguanine-DNA-methyltransferase promoter methylation and other strong prognostic factors

71 IRF6 expression, correlation with promoter methylation and p63 expression, and association

72 l transition, correlating with delayed Nanog promoter methylation and phenocopying loss of Eprn or Li

73 lance is at least in part caused by aberrant promoter methylation and subsequent transcriptional supp

74 derived clusterin resulted in decreased GAD1 promoter methylation and subsequent upregulation of GAD1

75 ressed gene 3 (PEG3) was associated with its promoter methylation and T2D status.

76 1) in zebrafish leads to a reduction in tnfa promoter methylation and the induction of tnfa expressio

77 ULK2 promoter methylation and transcript levels showed signif

78 matin loading of DNMT-1 and subsequent BRMS1 promoter methylation and transcriptional repression.

79 significantly associated with decreased MGMT promoter methylation and vice versa (1425.1 for methylat

80 orepinephrine-induced ROS production and the promoter methylation, and also restored PKCepsilon mRNA

81 recursive partitioning analysis class, MGMT promoter methylation, and geographical region, and rando

82 or, O(6)-methylguanine-DNA methyltransferase promoter methylation, and glioblastoma subtype.

83 es in the absence of loss-of-heterozygosity, promoter methylation, and mutations, we speculated that

84 ngly, norepinephrine-induced ROS production, promoter methylation, and PKCepsilon gene repression wer

85 EN genomic alterations (deletion, mutation), promoter methylation, and protein destabilization did no

86 homolog B (Caenorhabditis elegans) (LIN28B) promoter methylation, and reduced LIN28B expression.

87 miR-200a and miR-200b, silencing of SIP1 by promoter methylation, and retention of E-cadherin expres

88 mary luminal differentiation marker FoxA1 by promoter-methylation, and that is regulated by the Plk1

89 We found distinct patterns of promoter methylation around transcription start sites, w

90 nd oxidative stress response genes, based on promoter methylation array analysis.

91 Using genome-wide promoter methylation arrays, we show that human embryona

92 ort clinical development of detecting miR-31 promoter methylation as a novel biomarker.

93 rs in neuro-oncology presently are: (i) MGMT promoter methylation as a prognostic and predictive mark

94 rase specific for H3K4, is required for MDR1 promoter methylation, as knockdown of MLL1 resulted in a

95 is patients also exhibited differential TLR2 promoter methylation, as revealed by bisulfite DNA seque

96 gated the epigenetic inactivation of CDX1 by promoter methylation, as well as the functional link of

97 Of these, MDR1 promoter methylation associates with specific microbiomi

98 ed ROS resulted in an increase in PKCepsilon promoter methylation at Egr-1 and Sp-1 binding sites, le

99 DNA methylation analysis found increased promoter methylation at relapse.

100 a combination of copy number alteration and promoter methylation at the DNA level.

101 s2 expression was negatively correlated with promoter methylation at the individual level in maternal

102 sion and an inverse biphasic pattern of CDX1 promoter methylation; both are highly consistent with CD

103 n carriers and in sporadic tumors with BRCA1 promoter methylation but rarely in other breast cancers.

104 igenetically silenced in aggressive cells by promoter methylation, but 5-azacytidine treatment reacti

105 lele-specific differences exist only in MLH1 promoter methylation, but not gene expression.

106 bservations suggest that an increase in rDNA promoter methylation can result in decreased rRNA synthe

107 positive correlation between expression and promoter methylation, challenging the common dogma based

108 due to epigenetic silencing with associated promoter methylation; coding somatic mutations rarely oc

109 ading to a significantly higher degree of ER promoter methylation compared with parental cells.

110 ed expression or activity of NLRC5 caused by promoter methylation, copy number loss, or somatic mutat

111 correlation analyses, only cord blood NR3C1 promoter methylation correlated negatively with methylat

112 e levels of H3K27 acetylation and PGC-1alpha promoter methylation correlated significantly with the a

113 NSD1 promoter methylation correlated with SETD2 somatic mutat

114 PTEN promoter methylation data were acquired from an archived

115 ression of VEGFR2 in endothelial cells via a promoter methylation-dependent mechanism, and leads to d

116 Overall, promoter methylation differences were inversely correlat

117 We find that lung cancer cells with RASSF1A promoter methylation display constitutive nuclear YAP1 a

118 ation of certain signature genes silenced by promoter methylation (DOK2, miR-193a, and others) restor

119 thermore, we found that genes with converted promoter methylation during DMOG antagonism were associa

120 riations, including potentially inactivating promoter methylation events at 384 genes linked to human

121 d that ccRCC patients with low levels of CA9 promoter methylation had a higher survival rate.

122 ID4 promoter methylation has been reported in acute myeloid

123 The cluster comprising samples with higher-promoter methylation (High-M) had a poorer overall survi

124 egulated at three different levels involving promoter methylation, histone modification, and opposing

125 r prognostic value for OS compared with MGMT promoter methylation (HR, 1.77; 95% CI, 1.28-2.44; P < .

126 The other allele showed significant promoter methylation in 12 of 17 (71%) cases.

127 various degrees in CLL cells, and increased promoter methylation in a univariable analysis correlate

128 endogenous TET activity increases lytic EBV promoter methylation in an EBV-infected telomerase-immor

129 interaction model, providing evidence for IM promoter methylation in bAM.

130 miR-192 was downregulated by promoter methylation in both PDAC and chronic pancreatit

131 The association between body mass and promoter methylation in breast tumors was investigated i

132 decreased rRNA expression and increased rDNA promoter methylation in CD34(+) hematopoietic progenitor

133 methylation profiling revealed differential promoter methylation in cis with 146 of these differenti

134 We directly assessed gene promoter methylation in control mice and in mice pretrea

135 IFNgamma promoter methylation in cord white blood cells was assoc

136 ity for microsatellite instability (MSI) and promoter methylation in driving these phenomena forward

137 r (FRET) nanosensor technique to analyze the promoter methylation in early stage NSCLC tissue samples

138 and detected a significant increase in HER4 promoter methylation in HER4-negative breast tumors (P<0

139 ghlights specific alterations in global gene promoter methylation in HPV-driven OPSCCs and identifies

140 erformed a genome-wide analysis for aberrant promoter methylation in human CCs.

141 Notably, CDO1 is preferentially silenced by promoter methylation in human non-small cell lung cancer

142 pase recruitment domain (ASC) is silenced by promoter methylation in many types of tumors, yet ASC's

143 of FOXA1 expression and enhancement of FOXA1 promoter methylation in MCF-7 breast cancer cells, where

144 However, the role of PTEN promoter methylation in melanoma is not well understood.

145 s sought to elucidate the prevalence of PTEN promoter methylation in melanoma specimens, its relation

146 Promoter methylation in MLH1, MLH3, MSH3 and PMS2 was al

147 immunohistochemistry (IHC) and for MLH1 gene promoter methylation in MLH1-deficient cases.

148 e is known about how synaptic signals impact promoter methylation in neuronal nuclei.

149 clinical significance of CYGB expression and promoter methylation in non-small cell lung cancer (NSCL

150 existing clinically based RPA model and MGMT promoter methylation in NRG Oncology RTOG 0525.

151 over the past decade to describe CpG island promoter methylation in other tumor types, including bla

152 Lower NR3C1-1F promoter methylation in peripheral blood mononuclear cel

153 We verified HER4 promoter methylation in primary breast carcinomas and de

154 st study to demonstrate alterations of GR-1F promoter methylation in relation to parental PTSD and ne

155 nohistochemical staining and examined LINE-1 promoter methylation in representative cases.

156 The detection of tumor suppressor gene promoter methylation in sputum-derived exfoliated cells

157 ancer is mediated through differential SMAD3 promoter methylation in TAFs and provide new mechanistic

158 genes exhibit significantly lower levels of promoter methylation in the human brain than in the chim

159 e serous subtype associate with higher HNF1B-promoter methylation in these tumours.

160 In patients with glioblastoma, MGMT promoter methylation in tumor tissue was not more predic

161 In BAR-T cells, NOX5 mRNA and p16 promoter methylation increased after pulsed acid treatme

162 d including prostate ductal initiation, Cdh1 promoter methylation increases and its mRNA and protein

163 Unaltered levels of OCT4 promoter methylation indicated gene-specific effects.

164 GnT-V-null tumors was not due to changes in promoter methylation; instead, impaired her-2-mediated s

165 Moreover, we show that TrkC silencing by promoter methylation is a selective advantage for colore

166 Our results indicate that PTEN promoter methylation is an independent predictor for imp

167 Biological validation showed that PCSK9 promoter methylation is conserved across tissues and pos

168 IL-2Rgamma promoter methylation is induced in malignant T cells by

169 familial breast tumours revealed that FOXA1 promoter methylation is inversely correlated with the tr

170 We find that promoter methylation is maintained in this system, even

171 cell, tissue, and individual levels, whereas promoter methylation is more prominent in reinforcing fu

172 methyltransferase activity, suggesting that promoter methylation is one of the key epigenetic mechan

173 TFAP4 binding is absent on both alleles when promoter methylation is present.

174 While promoter methylation is relatively well characterized, t

175 We further show that PTPRT promoter methylation is significantly associated with se

176 tant mice and the finding that aberrant RHOX promoter methylation is strongly associated with abnorma

177 epigenetic silencing of RAD51C and BRCA1 by promoter methylation is strongly associated with signatu

178 Third, promoter methylation is widespread and associated with d

179 ely correlated with IFN-gamma and Foxp3 gene promoter methylation levels (P<.0011) (P<.0165).

180 Next, we quantified CDH1 promoter methylation levels in CDH1 mutation-positive fa

181 Furthermore, an association between the promoter methylation levels of IFNgamma and IL13 was mod

182 No significant difference in promoter methylation levels was shown between omega-3 PU

183 nce postnatal developmental patterns of gene promoter methylation linking early with disease risk.

184 esis and whose reduced expression due to DNA promoter methylation may lead to selective cervical tumo

185 Alterations in NR3C1-1F promoter methylation may reflect enduring changes result

186 bition in HNSCC cells, suggesting that PTPRT promoter methylation may serve as a predictive biomarker

187 d in the MiaPaCa2 cell line, suggesting that promoter methylation may silence Dab2 expression early i

188 Using a non-bias genome-wide promoter methylation microarray profiling method, we rev

189 N1 nasal epithelial mRNA expression and VNN1 promoter methylation might be clinically useful biomarke

190 ivated in hematopoietic and solid cancers by promoter methylation, miRNA-mediated silencing, and muta

191 nscription factor binding analyses indicated promoter methylation modified expression of key genes.

192 To confirm that TNFA promoter methylation modulated TNFA transcription, THP.1

193 Furthermore, high SPARC promoter methylation negatively correlated with disease-

194 on, via a mechanism not readily explained by promoter methylation nor the binding of transcription fa

195 early, and is apparent in adenomas, PCDHGC3 promoter methylation occurs later in the adenoma-carcino

196 We showed that WHR was associated with DNA promoter methylation of >/=1 of 3 genes in postmenopausa

197 This results in deficits in promoter methylation of activity-dependent genes, as wel

198 ive DNA methylation patterns, with decreased promoter methylation of CCL5, IL2RA and TBX21, genes enc

199 undance (P=0.04); lower cord blood leukocyte promoter methylation of CRH (P=0.05) and NR3C1 (P=0.04);

200 DNA promoter methylation of cyclin D1 regulators were assess

201 nced by microsatellite instability (MSI) and promoter methylation of DNA mismatch repair genes, is co

202 linked with Th1 polarization, and increased promoter methylation of FCER2, a low-affinity receptor f

203 promoter silencing, is also required for the promoter methylation of fructose-1,6-biphosphatase (FBP1

204 Mechanistically, COX2/PGE2 signaling induced promoter methylation of let-7, resulting in its downregu

205 Promoter methylation of mir-9 genes correlated with low

206 The role of the promoter methylation of O (6)-methylguanine-DNA methyltr

207 cetylation (H3K27 acetylation) and increased promoter methylation of peroxisome proliferator-activate

208 The overall genome CpG methylation and promoter methylation of PTEN and CDKN2A were unaffected

209 ultivariate Cox-regression analysis revealed promoter methylation of PTEN to be an independent negati

210 ression of SALL4 led to increased CpG island promoter methylation of silenced genes in various cell t

211 rnal choline intake yielded higher placental promoter methylation of the cortisol-regulating genes, c

212 om 93 colonic polyps and tested for MSI, and promoter methylation of the DNA mismatch repair genes ML

213 croRNA-mediated mechanism and by stimulating promoter methylation of the E-cadherin gene (Cdh1).

214 or determinant of resistance being a lack of promoter methylation of the gene encoding the repair pro

215 -case comparisons of tumors with and without promoter methylation of the genes.

216 the presence of Dnmt3a or Dnmt3b in de novo promoter methylation of the H2-Ab1 gene.

217 se of SCC-TAFs was associated with increased promoter methylation of the profibrotic TGFbeta transcri

218 ppo-mediated inhibition of YAP1 is lost upon promoter methylation of the RAS effector and hippo kinas

219 Specifically, we found that increased promoter methylation of the serotonin transporter gene p

220 Here we investigated promoter methylation of three genes regulating epithelia

221 itors, and this overexpression increased the promoter methylation of TSPYL5 potentially through DNMT3

222 In addition, promoter methylation of two translationally relevant gen

223 phenotype (C-CIMP) subgroup associated with promoter methylation of VEGF genes (FLT4, FLT1, and KDR)

224 llutants, NOS2 promoter haplotypes, and NOS2 promoter methylation on Feno levels in children.

225 argininosuccinate synthase (ASS1) by either promoter methylation or by HIF1alpha is associated with

226 , low BRCA1 mRNA expression (P = .03), BRCA1 promoter methylation (P = .04), p53 nonsense or frameshi

227 aplotypes were globally associated with NOS2 promoter methylation (P = 6.2 x 10(-8)).

228 plan-Meier analysis revealed that a combined promoter methylation pattern of low methylation levels i

229 wever, no significant difference in the TNFA promoter methylation pattern was observed in samples bio

230 deficient colorectal cancer tumors with MLH1 promoter methylation present fusions in kinase genes in

231 We found that the expression levels and promoter methylation profiles of more than half of the s

232 Here we integrated genome-wide DNA-promoter methylation profiling with gene expression prof

233 TERT promoter methylation provided an additional deregulatory

234 We find that RASSF1A promoter methylation reduces YAP phospho-S127, which der

235 1 expression, ZC3H18 depletion induces BRCA1 promoter methylation, reduces BRCA1 expression, disrupts

236 We hypothesized that promoter methylation regulates specific BCSC-related gen

237 ver both the current RTOG RPA model and MGMT promoter methylation, respectively, for patients with GB

238 ere performed to examine gene expression and promoter methylation, respectively.

239 We propose a novel mechanism whereby Cdh1 promoter methylation restricts Cdh1 abundance in develop

240 3b in liposarcoma cells was downregulated by promoter methylation, resulting at least in part from in

241 These results also suggest that promoter methylation status and miRNA expression levels

242 Discrepancies between MGMT promoter methylation status and treatment response in so

243 ght genes were then selected for analysis of promoter methylation status in cell lines and primary RC

244 ented a mixed cell population, the change in promoter methylation status in chronic periodontal disea

245 Promoter methylation status in long interspersed nucleot

246 nine (O(6)-MeG)-DNA methyltransferase (MGMT) promoter methylation status is accepted as a prognostic

247 anism of the downregulation, we examined the promoter methylation status of GPC5 gene.

248 lationship between maternal PAH exposure and promoter methylation status of IFNgamma and IL4.

249 This suggests that the DNA promoter methylation status of some steroid responsive g

250 MGMT promoter methylation status remained prognostic at tumor

251 The pooled results showed that MGMT promoter methylation status was significantly associated

252 clinical features and outcomes based on PTEN promoter methylation status were then analyzed using SPS

253 sence of oligodendroglial elements, and MGMT promoter methylation status, analysed by intention to tr

254 ymal, RTK I "PGFRA," RTK II "classic"), MGMT promoter methylation status, and hallmark copy number va

255 molecular markers (1p/19q co-deletion, MGMT promoter methylation status, and IDH1/IDH2 mutations).

256 1 expression negatively correlated with XAF1 promoter methylation status, and negatively correlate wi

257 rade, O6-methylguanine-DNA methyltransferase promoter methylation status, contrast enhancement, initi

258 nd SCMs is at least partially independent on promoter methylation status, suggesting a possible relat

259 hylguanine-DNA-methyltransferase gene (MGMT) promoter methylation status.

260 eexpress the silenced gene with no change in promoter methylation status.

261 promoter activity, independent of the MMP13 promoter methylation status.

262 Promoter methylation studies of top findings failed to e

263 fficult, and, when done, primarily relies on promoter methylation studies of tumour biopsy material a

264 In patients with MGMT promoter methylation, temozolomide monotherapy may have

265 ore, certain tumors show a high incidence of promoter methylation termed as the CpG island methylator

266 tion, as well as the functional link of CDX1 promoter methylation to the inflammatory NF-kappaB signa

267 3 transcriptional activity was suppressed by promoter methylation using a methylation-free in vitro s

268 In drug-resistant human EOC cell lines, Plk2 promoter methylation varied with the degree of drug resi

269 The frequency of promoter methylation was 20% for E-cadherin, 25.9% for p

270 NR3C1-1F promoter methylation was also associated with three func

271 ANO1 promoter methylation was also correlated with patient su

272 -transcriptase polymerase chain reaction and promoter methylation was assessed by pyrosequencing.

273 MGMT promoter methylation was assessed on patient tumor tissu

274 Although aberrant promoter methylation was associated with altered gene ex

275 Furthermore, in cell lines where GPX1 promoter methylation was associated with gene silencing,

276 nsferase isoform mu1 (GSTM1) and mu5 (GSTM5) promoter methylation was confirmed by CpG island bisulfi

277 SDHC promoter methylation was identified in 6 (18.7%) tumours

278 Finally, NR3C1-1F promoter methylation was inversely correlated with clini

279 ed in an experimental asthma model, and VNN1 promoter methylation was measured by means of bisulfite

280 Aberrant PTEN promoter methylation was not detected in 34 tumors.

281 ellite instability analyzed, and evidence of promoter methylation was observed in a significant propo

282 HOPX promoter methylation was observed in a subset of HNSCCs

283 rimary tumors, and a high frequency of GULP1 promoter methylation was observed in multiple sets of pr

284 Moreover, Oct4 and Nanog promoter methylation was reduced in the iPSCs generated

285 Significant promoter methylation was seen in MLH1, PMS2, MLH3 and MS

286 Lower GR-1F promoter methylation was significantly associated with g

287 A methylation patterns within the gene body; promoter methylation was unimportant.

288 ression are associated with increases in DNA promoter methylation, we explored the hypothesis that AV

289 e, by comparative analysis of expression and promoter methylation, we identify methylation sensitive

290 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arra

291 ra, Ferrara, Italy, IRF6 gene expression and promoter methylation were investigated in paraffin-embed

292 Furthermore, increased levels of HER4 promoter methylation were significantly associated with

293 erexpression of DAXX led to enhanced RASSF1A promoter methylation, whereas inhibition of DAXX reduced

294 pring with paternal PTSD showed higher GR-1F promoter methylation, whereas offspring with both matern

295 we found significant associations of bace-1 promoter methylation with beta-amyloid load among person

296 We correlate sub-genome-specific promoter methylation with decreased expression levels an

297 lation pattern correlates much stronger than promoter methylation with expression of putative target

298 SOCS1 gene promoter methylation, with its potential effects on the

299 ession variance is not explained by proximal promoter methylation, with the exception of genes that d

300 alpha) mRNA expression and decreased ERalpha promoter methylation within the BST.